Ettore Beghi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8398149/publications.pdf

Version: 2024-02-01

514	107,443	92	308
papers	citations	h-index	g-index
523	523	523	118672
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
2	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	13.7	7,664
3	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	13.7	5,847
4	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
5	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
6	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989
7	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
8	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
9	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
10	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
11	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
12	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	13.7	3,269
13	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
14	Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology, The, 2021, 20, 795-820.	10.2	2,308
15	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
16	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	13.7	1,879
17	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
18	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544

#	Article	IF	CITATIONS
19	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, The, 2017, 16, 877-897.	10.2	1,521
20	Cost of disorders of the brain in Europe 2010. European Neuropsychopharmacology, 2011, 21, 718-779.	0.7	1,253
21	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 310-323.	2.1	839
22	Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia, 2011, 52, 2-26.	5.1	836
23	Comment on Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005, 46, 1698-1699.	5.1	769
24	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
25	Recommendation for a definition of acute symptomatic seizure. Epilepsia, 2010, 51, 671-675.	5.1	657
26	Incidence of amyotrophic lateral sclerosis in Europe. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 385-390.	1.9	648
27	The epidemiology of epilepsy in Europe – a systematic review. European Journal of Neurology, 2005, 12, 245-253.	3.3	639
28	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
29	The Epidemiology of Epilepsy. Neuroepidemiology, 2020, 54, 185-191.	2.3	585
30	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
31	Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 357-375.	10.2	526
32	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
33	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
34	Combined analysis of risk factors for SUDEP. Epilepsia, 2011, 52, 1150-1159.	5.1	413
35	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
36	Predictors of epilepsy surgery outcome: a meta-analysis. Epilepsy Research, 2004, 62, 75-87.	1.6	375

#	Article	IF	CITATIONS
37	Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 6-11.	1.9	364
38	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	13.7	335
39	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
40	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330
41	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
42	The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health, The, 2020, 5, e551-e567.	10.0	290
43	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284
44	The risk of unprovoked seizures after encephalitis and meningitis. Neurology, 1988, 38, 1407-1407.	1.1	277
45	Burden of Neurological Disorders Across the US From 1990-2017. JAMA Neurology, 2021, 78, 165.	9.0	262
46	Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Network Open, 2021, 4, e2112131.	5.9	255
47	Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology, 1997, 49, 991-998.	1.1	242
48	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 870-905.	13.7	229
49	The burden of premature mortality of epilepsy in highâ€income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia, 2017, 58, 17-26.	5.1	228
50	Do antiepileptic drugs or generalized tonic–clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia, 2012, 53, 249-252.	5.1	224
51	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
52	Incidence and predictors of acute symptomatic seizures after stroke. Neurology, 2011, 77, 1785-1793.	1.1	219
53	Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. International Journal of Epidemiology, 2017, 46, dyw061.	1.9	202
54	First seizure definitions and worldwide incidence and mortality. Epilepsia, 2008, 49, 8-12.	5.1	200

#	Article	IF	Citations
55	Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981. Annals of Neurology, 1985, 18, 320-323.	5.3	197
56	Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology, The, 2012, 11 , $493-502$.	10.2	185
57	The epidemiology of ALS and the role of population-based registries. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 1150-1157.	3.8	168
58	Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1094-1098.	1.9	165
59	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	27.8	161
60	Morbidity and Accidents in Patients with Epilepsy: Results of a European Cohort Study. Epilepsia, 2002, 43, 1076-1083.	5.1	159
61	The first seizure and its management in adults and children. BMJ: British Medical Journal, 2006, 332, 339-342.	2.3	158
62	Estimating the Cost of Epilepsy in Europe: A Review with Economic Modeling. Epilepsia, 2007, 48, 2224-2233.	5.1	153
63	The natural history and prognosis of epilepsy. Epileptic Disorders, 2015, 17, 243-253.	1.3	152
64	Learning Disorders in Epilepsy. Epilepsia, 2006, 47, 14-18.	5.1	143
65	Longâ€term survival in amyotrophic lateral sclerosis: A populationâ€based study. Annals of Neurology, 2014, 75, 287-297.	5.3	141
66	Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Research, 2003, 57, 1-13.	1.6	136
67	Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors. Annals of the New York Academy of Sciences, 2003, 998, 413-423.	3.8	135
68	European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. European Stroke Journal, 2017, 2, 103-115.	5.5	133
69	Incidence of ALS in Lombardy, Italy. Neurology, 2007, 68, 141-145.	1.1	128
70	Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. Journal of the Neurological Sciences, 2003, 212, 31-36.	0.6	126
71	Incidence of Epileptic Syndromes in Rochester, Minnesota: 1980-1984. Epilepsia, 1999, 40, 1708-1714.	5.1	123
72	Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with metaâ€analysis of risk factors. Epilepsia, 2016, 57, 1205-1214.	5.1	122

#	Article	IF	CITATIONS
73	Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurology, The, 2004, 3, 618-621.	10.2	121
74	Chiropractic manipulation in the treatment of acute back pain and sciatica with disc protrusion: a randomized double-blind clinical trial of active and simulated spinal manipulations. Spine Journal, 2006, 6, 131-137.	1.3	121
75	Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 33-37.	1.9	121
76	Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Research, 2004, 60, 1-16.	1.6	120
77	Prognosis of myasthenia gravis: A multicenter follow-up study of 844 patients. Journal of the Neurological Sciences, 1991, 106, 213-220.	0.6	116
78	Adverse Reactions to Antiepileptic Drugs: A Multicenter Survey of Clinical Practice. Epilepsia, 1986, 27, 323-330.	5.1	115
79	Encephalitis and aseptic meningitis, Olmsted County, Minnesota, 1950-1981: I. Epidemiology. Annals of Neurology, 1984, 16, 283-294.	5.3	114
80	Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications, 2017, 8, 14774.	12.8	114
81	Antiepileptic drugs and the immune system. Epilepsia, 2011, 52, 40-44.	5.1	113
82	Withdrawal of antiepileptic drugs: Guidelines of the <scp>I</scp> talian <scp>L</scp> eague <scp>A</scp> gainst <scp>E</scp> pilepsy. Epilepsia, 2013, 54, 2-12.	5.1	112
83	Survival of Patients with Amyotrophic Lateral Sclerosis in a Population-Based Registry. Neuroepidemiology, 2005, 25, 114-119.	2.3	111
84	Amyotrophic lateral sclerosis, physical exercise, trauma and sports: Results of a population-based pilot case-control study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 289-292.	2.1	110
85	A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. Journal of Neurology, 1990, 237, 339-344.	3.6	108
86	Cluster headache prevalence in the Italian general population. Neurology, 2005, 64, 469-474.	1.1	108
87	Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 125-132.	1.9	108
88	Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Research, 2000, 41, 107-139.	1.6	107
89	The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 1-10.	2.1	107
90	Epidemiology of Central Nervous System Infections in Olmsted County, Minnesota, 1950-1981. Journal of Infectious Diseases, 1986, 154, 399-408.	4.0	106

#	Article	IF	Citations
91	Riluzole and amyotrophic lateral sclerosis survival: a populationâ€based study in southern Italy. European Journal of Neurology, 2007, 14, 262-268.	3.3	105
92	Addressing the burden of epilepsy: Many unmet needs. Pharmacological Research, 2016, 107, 79-84.	7.1	105
93	Guillain-Barré Syndrome. Archives of Neurology, 1985, 42, 1053.	4.5	102
94	Aging and the Epidemiology of Epilepsy. Neuroepidemiology, 2018, 51, 216-223.	2.3	101
95	Should Antiepileptic Drugs Be Withdrawn in Seizure-Free Patients?. CNS Drugs, 2004, 18, 201-212.	5.9	95
96	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 1593-1618.	13.7	92
97	Prevalence of epilepsy—An unknown quantity. Epilepsia, 2014, 55, 963-967.	5.1	91
98	Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 22-25.	1.9	90
99	The Economic Cost of Epilepsy: A Review of the Literature. Epilepsia, 2002, 43, 3-9.	5.1	90
100	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.1	90
101	The international European Academy of Neurology survey on neurological symptoms in patients with COVIDâ€19 infection. European Journal of Neurology, 2020, 27, 1727-1737.	3.3	90
102	Accidents in Patients with Epilepsy: Types, Circumstances, and Complications: A European Cohort Study. Epilepsia, 2004, 45, 667-672.	5.1	89
103	The changing picture of amyotrophic lateral sclerosis: lessons from European registers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 557-563.	1.9	89
104	Overview of Studies to Prevent Posttraumatic Epilepsy. Epilepsia, 2003, 44, 21-26.	5.1	88
105	Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. European Journal of Epidemiology, 2016, 31, 229-245.	5.7	87
106	Insulin Metabolism is Altered in Migraineurs: A New Pathogenic Mechanism for Migraine?. Headache, 2007, 47, 1436-1442.	3.9	86
107	Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population-based study. Journal of the Neurological Sciences, 2006, 250, 45-49.	0.6	85
108	Epilepsy and Psychiatric Disturbance. British Journal of Psychiatry, 1993, 163, 446-450.	2.8	83

#	Article	IF	CITATIONS
109	Headache, anxiety and depressive disorders: the HADAS study. Journal of Headache and Pain, 2010, 11, 141-150.	6.0	83
110	Correlation between Cognition and Behavior in Epilepsy. Epilepsia, 2006, 47, 34-39.	5.1	82
111	SIAMOC position paper on gait analysis in clinical practice: General requirements, methods and appropriateness. Results of an Italian consensus conference. Gait and Posture, 2017, 58, 252-260.	1.4	82
112	Prescribing patterns of antiepileptic drugs in Italy: a nationwide populationâ€based study in the years 2000–2005. European Journal of Neurology, 2007, 14, 1317-1321.	3.3	81
113	Epilepsy and quality of life in adults: A review of instruments. Epilepsy Research, 2005, 66, 23-44.	1.6	80
114	Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurologica Scandinavica, 2004, 110, 100-106.	2.1	79
115	Physical activity and amyotrophic lateral sclerosis: A European populationâ€based case–control study. Annals of Neurology, 2014, 75, 708-716.	5. 3	79
116	Barriers toward epilepsy surgery. A survey among practicing neurologists. Epilepsia, 2012, 53, 35-43.	5.1	78
117	Neurological Events Reported after COVIDâ€19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. Annals of Neurology, 2022, 91, 756-771.	5. 3	78
118	Hypothyroidism and polyneuropathy Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1420-1423.	1.9	74
119	The perceived burden of epilepsy: Impact on the quality of life of children and adolescents and their families. Seizure: the Journal of the British Epilepsy Association, 2015, 24, 93-101.	2.0	72
120	Epileptogenic drugs: a systematic review. Expert Review of Neurotherapeutics, 2006, 6, 575-589.	2.8	70
121	Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 729-734.	1.9	70
122	Prognosis of Epilepsy in Newly Referred Patients: A Multicenter Prospective Study. Epilepsia, 1988, 29, 236-243.	5.1	68
123	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.7	68
124	Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology, 2001, 56, 270-272.	1.1	67
125	BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. European Journal of Neurology, 2009, 16, 1240-1245.	3.3	67
126	<scp>ICD</scp> coding for epilepsy: Past, present, and futureâ€"A report by the International League Against Epilepsy Task Force on <scp>ICD</scp> codes in epilepsy. Epilepsia, 2015, 56, 348-355.	5.1	67

#	Article	IF	CITATIONS
127	Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology, 2006, 67, 2227-2229.	1.1	66
128	Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 626-629.	1.9	65
129	ALS multidisciplinary clinic and survival. Journal of Neurology, 2007, 254, 1107-1112.	3.6	65
130	Predictors of long survival in amyotrophic lateral sclerosis: A population-based study. Journal of the Neurological Sciences, 2008, 268, 28-32.	0.6	65
131	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. Drug Safety, 2019, 42, 347-363.	3.2	65
132	The costs of epilepsy in Italy. Epilepsy Research, 2002, 48, 207-216.	1.6	64
133	Direct Cost of Medical Management of Epilepsy among Adults in Italy: A Prospective Cost-of-Illness Study (EPICOS). Epilepsia, 2004, 45, 171-178.	5.1	64
134	Treatment of convulsive status epilepticus in childhood: Recommendations of the <scp>I</scp> talian <scp>L</scp> eague <scp>A</scp> gainst <scp>E</scp> pilepsy. Epilepsia, 2013, 54, 23-34.	5.1	64
135	Management of psychogenic nonâ€epileptic seizures: a multidisciplinary approach. European Journal of Neurology, 2019, 26, 205.	3.3	64
136	Trauma and amyotrophic lateral sclerosis: a case–control study from a populationâ€based registry. European Journal of Neurology, 2012, 19, 1509-1517.	3.3	63
137	Valproate, Carnitine Metabolism, and Biochemical Indicators of Liver Function. Epilepsia, 1990, 31, 346-352.	5.1	62
138	The Heterogeneity of Amyotrophic Lateral Sclerosis: A Possible Explanation of Treatment Failure. Current Medicinal Chemistry, 2007, 14, 3185-3200.	2.4	62
139	European consensus conference on unruptured brain AVMs treatment (Supported by EANS, ESMINT,) Tj ETQq $1\ 1$	0.784314 1.7	rgBT /Over
140	Reliability of the El Escorial Diagnostic Criteria for Amyotrophic Lateral Sclerosis. Neuroepidemiology, 2002, 21, 265-270.	2.3	58
141	Early ficolin-1 is a sensitive prognostic marker for functional outcome in ischemic stroke. Journal of Neuroinflammation, 2016, 13, 16.	7.2	58
142	Innate and adaptive immunity in human epilepsies. Epilepsia, 2017, 58, 57-68.	5.1	58
143	The semiology of psychogenic nonepileptic seizures revisited: Can video alone predict the diagnosis? Preliminary data from a prospective feasibility study. Epilepsia, 2016, 57, 777-785.	5.1	57
144	Adult-Onset Epilepsy in Presymptomatic Alzheimer's Disease: A Retrospective Study. Journal of Alzheimer's Disease, 2017, 60, 1267-1274.	2.6	57

#	Article	IF	Citations
145	The Management of Epilepsy in the 1990s. Drugs, 1995, 49, 680-694.	10.9	56
146	Pregnancy Registries in Epilepsy. Epilepsia, 2002, 42, 1422-1425.	5.1	55
147	Idiopathic Generalized Epilepsies of Adolescence. Epilepsia, 2006, 47, 107-110.	5.1	55
148	Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. European Neuropsychopharmacology, 2014, 24, 1289-1297.	0.7	55
149	Cost of epilepsy in Europea. European Journal of Neurology, 2005, 12, 54-58.	3.3	54
150	Mortality of Epilepsy in Developing Countries. Epilepsia, 2005, 46, 28-32.	5.1	54
151	Whole-blood global DNA methylation is increased in amyotrophic lateral sclerosis independently of age of onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 98-105.	1.7	54
152	Neurologic outcome of postanoxic refractory status epilepticus after aggressive treatment. Neurology, 2018, 91, e2153-e2162.	1.1	54
153	Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017. Lancet Public Health, The, 2019, 4, e645-e657.	10.0	54
154	Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia, 2010, 51, 37-42.	5.1	52
155	Past and present public knowledge and attitudes toward epilepsy in Italy. Epilepsy and Behavior, 2010, 18, 110-115.	1.7	52
156	Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. Archives of Physical Medicine and Rehabilitation, 2018, 99, 641-651.	0.9	51
157	Incidence of neonatal seizures, perinatal risk factors for epilepsy and mortality after neonatal seizures in the province of Parma, Italy. Epilepsia, 2018, 59, 1764-1773.	5.1	51
158	Hypertension, seizures, and epilepsy: a review on pathophysiology and management. Neurological Sciences, 2019, 40, 1775-1783.	1.9	51
159	Chronic Symmetric Symptomatic Polyneuropathy in the Elderly⠆⠆ A Field Screening Investigation of Risk Factors for Polyneuropathy in Two Italian Communities. Journal of Clinical Epidemiology, 1998, 51, 697-702.	5.0	50
160	Knowledge and attitudes toward epilepsy among primary and secondary schoolteachers in Italy. Epilepsy and Behavior, 2011, 22, 285-292.	1.7	50
161	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	3.4	50
162	COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions. Neuroepidemiology, 2020, 54, 364-369.	2.3	49

#	Article	IF	Citations
163	Homocysteine levels and amyotrophic lateral sclerosis: A possible link. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 140-147.	2.1	48
164	A case-control study of hormonal exposures as etiologic factors for ALS in women. Neurology, 2017, 89, 1283-1290.	1.1	48
165	Accidents and injuries in patients with epilepsy. Expert Review of Neurotherapeutics, 2009, 9, 291-298.	2.8	47
166	The sinister side of Italian soccer. Lancet Neurology, The, 2003, 2, 656-657.	10.2	46
167	The neurologist in the emergency department. An Italian nationwide epidemiological survey. Neurological Sciences, 2008, 29, 67-75.	1.9	46
168	Age-specific ALS incidence: a dose–response meta-analysis. European Journal of Epidemiology, 2018, 33, 621-634.	5.7	46
169	Diagnosis and Treatment of the First Epileptic Seizure: Guidelines of the Italian League Against Epilepsy. Epilepsia, 2006, 47, 2-8.	5.1	45
170	Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNF $<$ i $>\hat{l}\pm<$ /i>. Mediators of Inflammation, 2017, 2017, 1-16.	3.0	45
171	Multicentre, cross-cultural, population-based, case–control study of physical activity as risk factor for amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 797-803.	1.9	45
172	Depression and Altered Quality of Life in Women with Epilepsy of Childbearing Age. Epilepsia, 2004, 45, 64-70.	5.1	44
173	Risk factors for a first epileptic seizure after stroke: A case control study. Journal of the Neurological Sciences, 2009, 277, 138-142.	0.6	42
174	Health-related quality of life in adults with epilepsy: the effect of age, age at onset and duration of epilepsy in a multicentre Italian study. BMC Neurology, $2011, 11, 33$.	1.8	42
175	Alcohol use is a risk factor for a first generalized tonic-clonic seizure. Neurology, 1997, 48, 614-620.	1.1	41
176	Hemodynamic instability after extracranial carotid stenting. Acta Neurochirurgica, 2006, 148, 639-645.	1.7	41
177	Anticonvulsant drugs and bone metabolism. Acta Neurologica Scandinavica, 1986, 74, 284-288.	2.1	41
178	Risk of Guillain-Barré syndrome after 2010–2011 influenza vaccination. European Journal of Epidemiology, 2013, 28, 433-444.	5.7	41
179	Validation of healthcare administrative data for the diagnosis of epilepsy. Journal of Epidemiology and Community Health, 2013, 67, 1019-1024.	3.7	41
180	ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: Final Reportâ \in f 1998-2001. Epilepsia, 2002, 43, 668-673.	5.1	39

#	Article	IF	CITATIONS
181	Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 163-167.	2.1	39
182	The administration of rescue medication to children with prolonged acute convulsive seizures in the community: What happens in practice?. European Journal of Paediatric Neurology, 2013, 17, 14-23.	1.6	39
183	Epilepsy associated with Leukoaraiosis mainly affects temporal lobe: a casual or causal relationship?. Epilepsy Research, 2015, 109, 1-8.	1.6	39
184	Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. Journal of Neurology, 2022, 269, 2265-2274.	3.6	39
185	Classifications of Epileptic Syndromes: Advantages and Limitations for Evaluation of Childhood Epileptic Syndromes in Clinical Practice. Epilepsia, 1988, 29, 440-445.	5.1	38
186	A randomized controlled trial of recombinant interferon beta-1a in ALS. Neurology, 2000, 54, 469-469.	1.1	38
187	Proposal for a Multicenter Study on Epilepsy and Learning Disorders in Children. Epilepsia, 2001, 42, 10-12.	5.1	38
188	The Costs of Childhood Epilepsy in Italy: Comparative Findings from Three Health Care Settings. Epilepsia, 2001, 42, 641-646.	5.1	38
189	Neuropsychological and behavioural aspects in children and adolescents with idiopathic epilepsy at diagnosis and after 12 months of treatment. Seizure: the Journal of the British Epilepsy Association, 2010, 19, 540-546.	2.0	38
190	Acceptance of epilepsy surgery among adults with epilepsy â€" What do patients think?. Epilepsy and Behavior, 2012, 24, 352-358.	1.7	38
191	The European Academy of Neurology COVIDâ€19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVIDâ€19. European Journal of Neurology, 2021, 28, 3303-3323.	3.3	38
192	Headache and anxiety–depressive disorder comorbidity: the HADAS study. Neurological Sciences, 2007, 28, S217-S219.	1.9	37
193	Stroke and Alcohol Intake in a Hospital Population. Stroke, 1995, 26, 1691-1696.	2.0	37
194	Drug Treatment of Epilepsy. Drugs, 1986, 31, 249-265.	10.9	36
195	Hemorrhagic infarction: risk factors, clinical and tomographic features, and outcome A case-control study. Acta Neurologica Scandinavica, 1989, 80, 226-231.	2.1	36
196	Incidence of firstâ€ever ischemic and hemorrhagic stroke in a wellâ€defined community of southern Italy, 1993–1995. European Journal of Neurology, 2003, 10, 559-565.	3.3	36
197	Age at onset predicts good seizure outcome in sporadic non-lesional and mesial temporal sclerosis based temporal lobe epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 555-559.	1.9	36
198	Psychopathological comorbidities in medicationâ€overuse headache: a multicentre clinical study. European Journal of Neurology, 2016, 23, 85-91.	3.3	36

#	Article	IF	Citations
199	Primary headache and epilepsy: A multicenter cross-sectional study. Epilepsy and Behavior, 2012, 23, 342-347.	1.7	35
200	Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP). Neurological Sciences, 2015, 36, 1567-1574.	1.9	35
201	Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis. Neurological Sciences, 2017, 38, 399-406.	1.9	35
202	Arm rehabilitation in post stroke subjects: A randomized controlled trial on the efficacy of myoelectrically driven FES applied in a task-oriented approach. PLoS ONE, 2017, 12, e0188642.	2.5	35
203	Inter-rater reliability of the EEG reading in patients with childhood idiopathic epilepsy. Epilepsy Research, 2005, 66, 195-198.	1.6	34
204	Validity and reliability of the Italian version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31). Seizure: the Journal of the British Epilepsy Association, 2005, 14, 452-458.	2.0	34
205	Signs and symptoms at diagnosis of amyotrophic lateral sclerosis: a population-based study in southern Italy. European Journal of Neurology, 2006, 13, 789-792.	3.3	34
206	Prevalence and Incidence of Epilepsy in Italy Based on a Nationwide Database. Neuroepidemiology, 2014, 43, 228-232.	2.3	34
207	Emotional and affective disturbances in patients with epilepsy. Epilepsy and Behavior, 2002, 3, 255-261.	1.7	33
208	A Review of the Costs of Managing Childhood Epilepsy. Pharmacoeconomics, 2005, 23, 27-45.	3.3	33
209	Motor cortex stimulation for ALS: A double blind placebo-controlled study. Neuroscience Letters, 2009, 464, 18-21.	2.1	33
210	Are professional soccer players at higher risk for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 501-506.	1.7	33
211	An educational campaign about epilepsy among Italian primary school teachers. 2. The results of a focused training program. Epilepsy and Behavior, 2015, 42, 93-97.	1.7	33
212	Management of epilepsy in brain tumors. Neurological Sciences, 2019, 40, 2217-2234.	1.9	33
213	The prevalence of parkinsonism in Italy: An epidemiological survey of the disease in general practice. Movement Disorders, 1994, 9, 403-408.	3.9	32
214	Focus on the heterogeneity of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 485-495.	1.7	32
215	The global cost of epilepsy: A systematic review and extrapolation. Epilepsia, 2022, 63, 892-903.	5.1	32
216	Validity of hospital discharge diagnoses for the assessment of the prevalence and incidence of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 99-104.	1.2	31

#	Article	IF	CITATIONS
217	Prevalence and Characteristics of Epilepsy in the Aeolian Islands. Epilepsia, 2005, 46, 1828-1835.	5.1	31
218	Longâ€term applicability of the new <scp>ILAE</scp> definition of epilepsy. Results from the <scp>PRO</scp> â€ <scp>LONG</scp> study. Epilepsia, 2017, 58, 1518-1523.	5.1	31
219	Epilepsy, antiepileptic drugs and dementia. Current Opinion in Neurology, 2020, 33, 191-197.	3.6	31
220	Effects of lockdown on emergency room admissions for psychiatric evaluation: an observational study from the AUSL Romagna, Italy. International Journal of Psychiatry in Clinical Practice, 2021, 25, 135-139.	2.4	31
221	Validity of hospital discharge diagnoses for public health surveillance of the Guillain-BarrÃ ^{**} syndrome. Neurological Sciences, 2002, 23, 113-117.	1.9	30
222	Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2017, 10, 99.	2.9	30
223	Increased risk and early onset of ALS in professional players from Italian Soccer Teams. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 403-409.	1.7	30
224	The Curing Coma Campaign International Survey on Coma Epidemiology, Evaluation, and Therapy (COME TOGETHER). Neurocritical Care, 2022, 37, 47-59.	2.4	30
225	Cost of Epilepsy: Contrast of Methodologies in United States and European Studies. Epilepsia, 1999, 40, 14-18.	5.1	29
226	Risk factors for a first generalized tonic-clonic seizure in adult life. Neurological Sciences, 2002, 23, 99-106.	1.9	29
227	ALS and military service. Neurology, 2005, 64, 6-7.	1.1	29
228	Health-related quality of life in epilepsy: Findings obtained with a new Italian instrument. Epilepsy and Behavior, 2008, 13, 119-126.	1.7	29
229	Risk factors for tumor occurrence in patients with myasthenia gravis. Journal of Neurology, 2009, 256, 1221-1227.	3.6	29
230	Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. Journal of Neurology, 2018, 265, 817-827.	3.6	29
231	Amyotrophic lateral sclerosis and food intake. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 267-274.	1.7	29
232	Surgery for epilepsy: Assessing evidence from observational studies. Epilepsy Research, 2006, 70, 97-102.	1.6	28
233	Prevalence and incidence of epilepsy in a wellâ€defined population of Northern Italy. Epilepsia, 2014, 55, 1526-1533.	5.1	28
234	A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy and Behavior, 2016, 55, 30-37.	1.7	28

#	Article	IF	CITATIONS
235	Symptoms of anxiety and depression and family's quality of life in children and adolescents with epilepsy. Epilepsy and Behavior, 2018, 79, 146-153.	1.7	28
236	Adverse Reactions to Antiepileptic Drugs: A Followâ€Up Study of 355 Patients with Chronic Antiepileptic Drug Treatment. Epilepsia, 1988, 29, 787-793.	5.1	27
237	Morbidity in Patients with Epilepsy: Type and Complications: A European Cohort Study. Epilepsia, 2004, 45, 71-76.	5.1	27
238	Cost of disorders of the brain in Italy. Neurological Sciences, 2008, 29, 99-107.	1.9	27
239	AED discontinuation may not be dangerous in seizure-free patients. Journal of Neural Transmission, 2011, 118, 187-191.	2.8	27
240	A Multicentric Prospective Incidence Study of Guillain-Barr \tilde{A} © Syndrome in Italy. The ITANG Study. Neuroepidemiology, 2015, 45, 90-99.	2.3	27
241	Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. European Journal of Neurology, 2020, 27, 136-143.	3.3	27
242	EAN consensus statement for management of patients with neurological diseases during the COVIDâ€19 pandemic. European Journal of Neurology, 2021, 28, 7-14.	3.3	27
243	Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: An Italian multicenter prospective observational study. Epilepsy and Behavior, 2013, 28, 494-500.	1.7	26
244	Extrapyramidal and cognitive signs in amyotrophic lateral sclerosis: A population based cross-sectional study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 324-330.	1.7	26
245	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.7	26
246	Association between alcohol exposure and the risk of amyotrophic lateral sclerosis in the Euro-MOTOR study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 11-19.	1.9	26
247	Prognostic patterns and predictors in epilepsy: a multicentre study (PRO-LONG). Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1276-1285.	1.9	26
248	NeuroCOVID: it's time to join forces globally. Lancet Neurology, The, 2020, 19, 805-806.	10.2	26
249	Reliability of instrumented movement analysis as outcome measure in Charcot–Marie–Tooth disease: Results from a multitask locomotor protocol. Gait and Posture, 2011, 34, 36-43.	1.4	25
250	Headache, eating and sleeping behaviors and lifestyle factors in preadolescents and adolescents: preliminary results from an Italian population study. Neurological Sciences, 2012, 33, 87-90.	1.9	25
251	European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. European Journal of Neurology, 2021, 28, 2831-2845.	3 . 3	25
252	Antiepileptic Drugs as 'Tracers' of Disease. Neuroepidemiology, 1991, 10, 33-41.	2.3	24

#	Article	IF	CITATIONS
253	Accuracy of Death Certificates for Amyotrophic Lateral Sclerosis Varies Significantly from North to South of Italy: Implications for Mortality Studies. Neuroepidemiology, 2004, 23, 73-77.	2.3	24
254	Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases. Neurological Sciences, 2004, 25, 122-9.	1.9	24
255	Mortality in Patients with a First Unprovoked Seizure. Epilepsia, 2005, 46, 40-42.	5.1	24
256	Epilepsy and driving. BMJ: British Medical Journal, 2005, 331, 60-61.	2.3	24
257	Acceptance of epilepsy surgery in the pediatric age — What the parents think and what the doctors can do. Epilepsy and Behavior, 2013, 29, 112-120.	1.7	24
258	Longâ€term prognosis of epilepsy, prognostic patterns and drug resistance: a populationâ€based study. European Journal of Neurology, 2016, 23, 1218-1227.	3.3	24
259	Epilepsy and Everyday Life Risks. Neuroepidemiology, 1997, 16, 207-216.	2.3	23
260	Cross-Country Measures for Monitoring Epilepsy Care. Epilepsia, 2007, 48, 990-1001.	5.1	23
261	EFFECTS OF RATION/SIZING DRUG TREATMENT OF PATIENTS WITH EPILEPSY AND MENTAL RETARDATION. Developmental Medicine and Child Neurology, 2008, 29, 363-369.	2.1	23
262	Revising the ICD-10 codes for epilepsy and seizures. Epilepsia, 2012, 53, 3-5.	5.1	23
263	Status epilepticus in Auckland, New Zealand: Incidence, etiology, and outcomes. Epilepsia, 2019, 60, 1552-1564.	5.1	23
264	Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center. PLoS ONE, 2017, 12, e0180470.	2.5	23
265	Incidence, risk factors and short-term mortality of stroke in Vittoria, southern Italy. Neurological Sciences, 2002, 23, 15-21.	1.9	22
266	Validation of a Questionnaire for the Detection of Cluster Headache. Headache, 2005, 45, 644-652.	3.9	22
267	General conclusions and recommendations. Epilepsia, 2008, 49, 58-61.	5.1	22
268	An educational campaign toward epilepsy among Italian primary school teachers. Epilepsy and Behavior, 2014, 32, 84-91.	1.7	22
269	Referral bias in ALS epidemiological studies. PLoS ONE, 2018, 13, e0195821.	2.5	22
270	Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1092-1099.	1.9	22

#	Article	IF	CITATIONS
271	Comorbidities in patients with epilepsy: Frequency, mechanisms and effects on longâ€term outcome. Epilepsia, 2021, 62, 2395-2404.	5.1	22
272	High Prevalence of Major Neurological Disorders in Two Albanian Communities: Results of a Door-to-Door Survey. Neuroepidemiology, 2012, 38, 138-147.	2.3	21
273	Are we failing to provide adequate rescue medication to children at risk of prolonged convulsive seizures in schools?. Archives of Disease in Childhood, 2013, 98, 777-780.	1.9	21
274	Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?. Cytotherapy, 2016, 18, 1471-1475.	0.7	21
275	Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy. Neuroepidemiology, 2016, 47, 38-45.	2.3	21
276	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. Journal of Neurology, 2022, 269, 2080-2098.	3.6	21
277	Does headache represent a clinical marker in early diagnosis of cerebral venous thrombosis? A prospective multicentric study. Neurological Sciences, 2004, 25, s298-s299.	1.9	20
278	Economic Analysis of NewerÂAntiepileptic Drugs. CNS Drugs, 2008, 22, 861-875.	5.9	20
279	Time to Hospital Admission and Start of Treatment in Patients with Ischemic Stroke in Northern Italy and Predictors of Delay. European Neurology, 2013, 70, 349-355.	1.4	20
280	A Noninvasive Neuroprosthesis Augments Hand Grasp Force in Individuals with Cervical Spinal Cord Injury: The Functional and Therapeutic Effects. Scientific World Journal, The, 2013, 2013, 1-7.	2.1	20
281	Knowledge and attitudes towards epilepsy in Zambia: A questionnaire survey. Epilepsy and Behavior, 2014, 34, 42-46.	1.7	20
282	Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (<scp>ALS</scp>) patients in six French <scp>ALS</scp> centres. European Journal of Neurology, 2016, 23, 787-795.	3.3	20
283	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane Library, 2016, , CD007144.	2.8	20
284	Educational and Exercise Intervention to Prevent Falls and Improve Participation in Subjects With Neurological Conditions: The NEUROFALL Randomized Controlled Trial. Frontiers in Neurology, 2019, 10, 865.	2.4	20
285	Associations of Electric Shock and Extremely Low-Frequency Magnetic Field Exposure With the Risk of Amyotrophic Lateral Sclerosis. American Journal of Epidemiology, 2019, 188, 796-805.	3.4	20
286	Effect modification of the association between total cigarette smoking and ALS risk by intensity, duration and time-since-quitting: Euro-MOTOR. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 33-39.	1.9	20
287	<scp>Guillainâ€Barré</scp> syndrome and <scp>COVID</scp> â€19: A 1â€year observational multicenter study European Journal of Neurology, 2022, 29, 3358-3367.		20
288	Chronic Symmetric Polyneuropathy in the Elderly. Neuroepidemiology, 1993, 12, 96-105.	2.3	19

#	Article	IF	Citations
289	The concept of the epilepsy syndrome: How useful is it in clinical practice?. Epilepsia, 2009, 50, 4-10.	5.1	19
290	Migraine with aura with onset in childhood and adolescence: Long-term natural history and prognostic factors. Cephalalgia, 2010, 30, 674-681.	3.9	19
291	Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 924-927.	1.9	19
292	Family history and frontal lobe seizures predict long-term remission in newly diagnosed cryptogenic focal epilepsy. Epilepsy Research, 2013, 107, 101-108.	1.6	19
293	Stroke epidemiology and COVID-19 pandemic. Current Opinion in Neurology, 2021, 34, 3-10.	3.6	19
294	Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia, 2017, 58, 1524-1532.	5.1	19
295	The Guillain-BarrÃ" Syndrome (GBS). Italian Journal of Neurological Sciences, 1996, 17, 355-361.	0.1	18
296	Accidents at work among people with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 313-319.	2.0	18
297	127th ENMC International Workshop: Implementation of a European Registry of ALS Naarden, The Netherlands, 8–10 October 2004. Neuromuscular Disorders, 2006, 16, 46-53.	0.6	18
298	High sensitivity C-reactive protein predicts the development of new carotid artery plaques in older persons. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 776-782.	2.6	18
299	A New Self-Report Quality of Life Questionnaire for Children With Neuromuscular Disorders. Journal of Child Neurology, 2014, 29, 167-181.	1.4	18
300	Short―and longâ€ŧerm outcome and predictors in an international cohort of patients with neuroâ€COVIDâ€19. European Journal of Neurology, 2022, 29, 1663-1684.	3.3	18
301	Antiepileptic Drugs and Peripheral Nerve Function: A Multicenter Screening Investigation of 141 Patients with Chronic Treatment. Epilepsia, 1993, 34, 323-331.	5.1	17
302	The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids. Neurochemistry International, 1995, 27, 467-472.	3.8	17
303	Diazepam binding inhibitor (DBI) in the plasma of pediatric and adult epileptic patients. Epilepsy Research, 1998, 29, 129-134.	1.6	17
304	Chronic alcohol use and first symptomatic epileptic seizures. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 495-499.	1.9	17
305	Diabetes mellitus: a risk factor for seizures in the elderly—a population-based study. Acta Diabetologica, 2017, 54, 863-870.	2.5	17
306	Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 79-96.	2.3	17

#	Article	IF	Citations
307	Social functions and socioeconomic vulnerability in epilepsy. Epilepsy and Behavior, 2019, 100, 106363.	1.7	17
308	Multicentre, population-based, case–control study of particulates, combustion products and amyotrophic lateral sclerosis risk. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 854-860.	1.9	17
309	Rational Use of EEG in Adults in Clinical Practice. Journal of Clinical Neurophysiology, 1999, 16, 456.	1.7	17
310	Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: recent findings and achievements from a network of laboratories. Neurological Sciences, 2004, 25, s41-s60.	1.9	16
311	Prevalence of Primary Focal or Segmental Dystonia in Adults in the District of Foggia, Southern Italy: A Service-Based Study. Neuroepidemiology, 2009, 33, 117-123.	2.3	16
312	External Validation of a Prognostic Model for Seizure Recurrence Following a First Unprovoked Seizure and Implications for Driving. PLoS ONE, 2014, 9, e99063.	2.5	16
313	Critical issues in ALS case-control studies: the case of the Euro-MOTOR study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 411-418.	1.7	16
314	Neurological outcome of postanoxic refractory status epilepticus after aggressive treatment. Epilepsy and Behavior, 2019, 101, 106374.	1.7	16
315	Approaches to Understanding <scp>COVID</scp> â€19 and its Neurological Associations. Annals of Neurology, 2021, 89, 1059-1067.	5.3	16
316	Prognostic factors in ALS: A critical review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 0, , 1-14.	2.1	16
317	The international classification of the epilepsies and epileptic syndromes. Epilepsy Research, 2000, 41, 223-234.	1.6	15
318	Psychotherapy versus usual care in pediatric migraine and tension-type headache: a single-blind controlled pilot study. Italian Journal of Pediatrics, 2014, 40, 6.	2.6	15
319	Patients' and caregivers' contributions for differentiating epileptic from psychogenic nonepileptic seizures. Value and limitations of self-reporting questionnaires: A pilot study. Seizure: the Journal of the British Epilepsy Association, 2017, 53, 66-71.	2.0	15
320	Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 63-77.	2.3	15
321	Incidence of Epilepsy after Neonatal Seizures: A Population-Based Study. Neuroepidemiology, 2019, 52, 144-151.	2.3	15
322	Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: Data from the Italian CIDP database. Journal of the Peripheral Nervous System, 2020, 25, 152-161.	3.1	15
323	Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria?. European Journal of Neurology, 2021, 28, 620-629.	3.3	15
324	Correlation among lesion level, muscle strength and hand function in cervical spinal cord injury. European Journal of Physical and Rehabilitation Medicine, 2014, 50, 31-8.	2.2	15

#	Article	IF	CITATIONS
325	Ataxic hemiparesis syndrome: clinical and CT study of 20 new cases and review of the literature. Italian Journal of Neurological Sciences, 1986, 7, 51-59.	0.1	14
326	EFFECT OF REFERRAL BIAS ON ASSESSING SURVIVAL IN ALS. Neurology, 2007, 69, 939-940.	1.1	14
327	The Effectiveness of Hospitalization in the Treatment of Paediatric Idiopathic Headache Patients. Psychopathology, 2007, 40, 1-7.	1.5	14
328	Description and Validation of an Italian ICHDâ€Nâ€Based Questionnaire for Use in Epidemiological Research. Headache, 2012, 52, 1262-1282.	3.9	14
329	Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions. Journal of Geriatric Oncology, 2017, 8, 289-295.	1.0	14
330	Engaging psychiatrists in the diagnosis of psychogenic nonepileptic seizures. What can they contribute? Seizure: the Journal of the British Epilepsy Association, 2017, 52, 182-187.	2.0	14
331	A plea for equitable global access to COVIDâ€19 diagnostics, vaccination and therapy: The NeuroCOVIDâ€19 Task Force of the European Academy of Neurology. European Journal of Neurology, 2021, 28, 3849-3855.	3.3	14
332	A Mouse Model of Familial ALS Has Increased CNS Levels of Endogenous Ubiquinol9/10 and Does Not Benefit from Exogenous Administration of Ubiquinol10. PLoS ONE, 2013, 8, e69540.	2.5	14
333	Practice guidelines: a more rational approach to diagnosis and treatment and a more effective use of health care resources. Italian Journal of Neurological Sciences, 1998, 19, 120-123.	0.1	13
334	Utilization and Costs of Antiepileptic Drugs in the Elderly. Drugs and Aging, 2009, 26, 157-168.	2.7	13
335	Treating epilepsy across its different stages. Therapeutic Advances in Neurological Disorders, 2010, 3, 85-92.	3.5	13
336	Satisfaction with antiepileptic drugs in children and adolescents with newly diagnosed and chronic epilepsy. Epilepsy Research, 2012, 100, 142-151.	1.6	13
337	Comprehensive educational plan for patients with epilepsy and comorbidity (EDU-COM): a pragmatic randomised trial. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 889-894.	1.9	13
338	Non-Suicidal Self-Injury in Russian Patients with Suicidal Ideation. Archives of Suicide Research, 2022, 26, 776-800.	2.3	13
339	Primary prevention of COVID‶9: Advocacy for vaccination from a neurological perspective. European Journal of Neurology, 2021, 28, 3226-3229.	3.3	13
340	Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a dose–response meta-analysis. Journal of Neurology, 2021, 268, 2973-2984.	3.6	13
341	Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?. CNS and Neurological Disorders - Drug Targets, 2013, 12, 426-435.	1.4	13
342	COVID‶9 vaccination hesitancy among people with chronic neurological disorders: A position paper. European Journal of Neurology, 2022, 29, 2163-2172.	3.3	13

#	Article	IF	Citations
343	Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports. Cephalalgia, 2022, 42, 1207-1217.	3.9	13
344	Prevalence, Characteristics, and Patterns of Health Care Use for Chronic Headache in Two Areas of Italy. Results of A Questionnaire Interview in General Practice. Cephalalgia, 2003, 23, 175-182.	3.9	12
345	Are Vascular Disorders More Prevalent in the Relatives of Children and Adolescents with Migraine?. Cephalalgia, 2003, 23, 887-891.	3.9	12
346	Management of headache in emergency room. Neurological Sciences, 2004, 25, s187-s189.	1.9	12
347	Amyotrophic lateral sclerosis and soccer: A different epidemiological approach strengthen the previous findings. Journal of the Neurological Sciences, 2008, 269, 187-188.	0.6	12
348	Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis. European Journal of Inflammation, 2009, 7, 39-44.	0.5	12
349	New classification proposals for epilepsy: A real advancement in the nosography of the disease?. Epilepsia, 2011, 52, 1197-1198.	5.1	12
350	Epidemiologic aspects: Lost in transition. Epilepsia, 2014, 55, 3-7.	5.1	12
351	The direct costs of epilepsy in Russia. A prospective cost-of-illness study from a single center in Moscow. Epilepsy and Behavior, 2016, 64, 122-126.	1.7	12
352	Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. Neurological Sciences, 2016, 37, 579-583.	1.9	12
353	Why talking about psychiatric comorbidity in PNES?. Epilepsy and Behavior, 2017, 75, 276.	1.7	12
354	Mobility Disorders in Stroke, Parkinson Disease, and Multiple Sclerosis. American Journal of Physical Medicine and Rehabilitation, 2020, 99, 41-47.	1.4	12
355	Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment. Epilepsia, 2022, 63, 335-351.	5.1	12
356	Quality of Care of Epilepsy in Italy: A Multiâ€hospital Survey of Diagnosis and Treatment of 1104 Epileptic Patients. Epilepsia, 1982, 23, 133-148.	5.1	11
357	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1-dopa, 1-deprenyl and dopaminoagonists. Study design and short term results. Italian Journal of Neurological Sciences, 1992, 13, 735-739.	0.1	11
358	Motor Neuron Disease in the Padua District of Italy: An Epidemiological Study. Neuroepidemiology, 1996, 15, 173-179.	2.3	11
359	Injuries in patients with epilepsy. Lancet Neurology, The, 2005, 4, 71-72.	10.2	11
360	Merits of a New Drug Trial for ALS?. Science, 2005, 308, 632b-633b.	12.6	11

#	Article	IF	CITATIONS
361	Diabetic polyneuropathy in the elderly. Acta Neurologica Scandinavica, 1997, 96, 223-228.	2.1	11
362	Distinct cytokine patterns associated with different forms of chronic dysimmune neuropathy. Muscle and Nerve, 2010, 42, 864-870.	2.2	11
363	Reliability of Clinical Diagnosis of Dystonia. Neuroepidemiology, 2014, 43, 213-219.	2.3	11
364	Inâ€hospital costs in patients with seizures and epilepsy after stroke. Epilepsia, 2015, 56, 1309-1313.	5.1	11
365	The long-term prognosis of newly diagnosed epilepsy in Egypt: A retrospective cohort study from an epilepsy center in Greater Cairo. Seizure: the Journal of the British Epilepsy Association, 2016, 41, 86-95.	2.0	11
366	Antidepressant effect of vagal nerve stimulation in epilepsy patients: a systematic review. Neurological Sciences, 2020, 41, 3075-3084.	1.9	11
367	The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids. Neurochemistry International, 1995, 27, 467-472.	3.8	11
368	Risk factors for a first epileptic seizure symptomatic of brain tumour or brain vascular malformation. Swiss Medical Weekly, 2011, 141, w13155.	1.6	11
369	Mortality in patients with psychogenic non-epileptic seizures a population-based cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 379-385.	1.9	11
370	Modeling drop-outs in amyotrophic lateral sclerosis. Contemporary Clinical Trials, 2012, 33, 218-222.	1.8	10
371	Clinical and stabilometric measures predicting falls in Parkinson disease/parkinsonisms. Acta Neurologica Scandinavica, 2015, 132, 235-241.	2.1	10
372	Migraine-specific quality of life questionnaire and relapse of medication overuse headache. BMC Neurology, 2015, 15, 85.	1.8	10
373	The role of single-nucleotide variants of the energy metabolism-linked genes <i>SIRT3</i> , <i>PPARGC1A</i> and <i>APOE</i> in amyotrophic lateral sclerosis risk. Genes and Genetic Systems, 2016, 91, 301-309.	0.7	10
374	The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study. Epilepsy and Behavior, 2020, 102, 106641.	1.7	10
375	Antiepileptic drug toxicity: Definition and mechanism of action. Italian Journal of Neurological Sciences, 1986, 7, 209-222.	0.1	9
376	Polyneuropathy in an Adult Hospital Population. Neuroepidemiology, 1988, 7, 23-28.	2.3	9
377	Recurrence after a first unprovoked seizure. Is it still a controversial issue?. Seizure: the Journal of the British Epilepsy Association, 1993, 2, 5-10.	2.0	9
378	The Cochrane Collaboration: Systematic Reviews and Their Relevance to Epilepsy. Epilepsia, 1996, 37, 917-921.	5.1	9

#	Article	IF	Citations
379	A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Neurological Sciences, 2005, 26, s171-s173.	1.9	9
380	Psychiatric events in epilepsy. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 586-592.	2.0	9
381	Introduction. Epilepsia, 2013, 54, 1-1.	5.1	9
382	Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 77-84.	1.7	9
383	The ILAE classification of seizures and epilepsies: implications for the clinic. Expert Review of Neurotherapeutics, 2018, 18, 179-183.	2.8	9
384	Discontinuation of antiseizure medications in seizure-free patients with long-term follow-up: Patients' profile, seizure recurrence, and risk factors. Epilepsy and Behavior, 2021, 117, 107871.	1.7	9
385	The Use of Anticonvulsants in Neurological Conditions Other Than Epilepsy. CNS Drugs, 1999, 11, 61-82.	5.9	8
386	Anticonvulsants and Peripheral Nerve Function. Clinical Drug Investigation, 2000, 20, 173-180.	2.2	8
387	Early invasive treatment (endarterectomy vs. stenting) of moderate-to-severe carotid stenosis in patients with transient ischaemic attack or minor stroke. Neurological Sciences, 2005, 26, s31-s33.	1.9	8
388	Evidence for a rapid action of levetiracetam compared to topiramate in refractory partial epilepsy. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 112-116.	2.0	8
389	Plasma amino acids patterns and age of onset of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 371-375.	1.7	8
390	The administration of rescue medication to children with prolonged acute convulsive seizures in a non-hospital setting: an exploratory survey of healthcare professionals' perspectives. European Journal of Pediatrics, 2014, 173, 773-779.	2.7	8
391	Temozolomide and thalidomide in the treatment of glioblastoma multiforme. Anticancer Research, 2007, 27, 1067-71.	1.1	8
392	Update of Trends in Mortality from Stroke in Italy from 1955 to 1987. Neuroepidemiology, 1992, 11, 196-203.	2.3	7
393	Cerebrovascular disorders and alcohol intake: preliminary results of a case-control study. Italian Journal of Neurological Sciences, 1992, 13, 209-214.	0.1	7
394	Decreased density of lymphocyte benzodiazepine receptors in drug-resistant epileptic patients. Epilepsy Research, 1997, 27, 181-185.	1.6	7
395	Classification of amyotrophic lateral sclerosis cases at presentation in epidemiological studies. Neurological Sciences, 2005, 26, 330-333.	1.9	7
396	Response to rehabilitation of children and adolescents with epilepsy. Epilepsy and Behavior, 2011, 20, 79-82.	1.7	7

#	Article	IF	CITATIONS
397	Stroke Management in Northern Lombardy: Organization of An Emergency-Urgency Network and Development of a Connection between Prehospital and In-Hospital Settings. International Journal of Stroke, 2012, 7, 527-533.	5.9	7
398	Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 385-388.	1.7	7
399	New classification of seizures and epilepsies — an advance?. Nature Reviews Neurology, 2017, 13, 324-325.	10.1	7
400	History of violence/maltreatment and psychogenic non-epileptic seizures. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 8-12.	2.0	7
401	The epidemiology of amyotrophic lateral sclerosis in Moscow (Russia). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 410-415.	1.7	7
402	Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE). Epilepsy and Behavior, 2021, 116, 107804.	1.7	7
403	Lessons learned from people with neurological diseases at the time of COVIDâ€19: The EFNAâ€EAN survey. European Journal of Neurology, 2022, 29, 318-323.	3.3	7
404	Predictive factors of Status Epilepticus and its recurrence in patients with adult–onset seizures: A multicenter, long follow–up cohort study. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 397-401.	2.0	7
405	A randomized trial on the treatment of the first epileptic seizure scientific background, rationale, study design and protocol. Italian Journal of Neurological Sciences, 1993, 14, 293-301.	0.1	6
406	New ideas for therapy in ALS: Critical considerations. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2006, 7, 126-127.	2.1	6
407	Randomised controlled monotherapy trials: which comparators to use?. Epileptic Disorders, 2012, 14, 235-241.	1.3	6
408	Voluptuary Habits and Risk of Frontotemporal Dementia: A Case Control Retrospective Study. Journal of Alzheimer's Disease, 2017, 60, 335-340.	2.6	6
409	No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk—An analysis of Finnish health register and German health insurance data. Epilepsia, 2018, 59, 1303-1306.	5.1	6
410	Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study. Journal of the Neurological Sciences, 2019, 405, 116411.	0.6	6
411	Treatment of epilepsy in light of the most recent advances. Lancet Neurology, The, 2019, 18, 7-8.	10.2	6
412	Redistribution of garbage codes to underlying causes of death: a systematic analysis on Italy and a comparison with most populous Western European countries based on the Global Burden of Disease Study 2019. European Journal of Public Health, 2022, 32, 456-462.	0.3	6
413	Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study. Neurological Sciences, 2022, 43, 5133-5141.	1.9	6
414	Stenting of Atherosclerotic Stenoses of the Extracranial Carotid Artery. Acta Neurochirurgica, 2001, 143, 1005-1011.	1.7	5

#	Article	IF	CITATIONS
415	Acute medical complications in patients admitted to a stroke unit and safe transfer to rehabilitation. Neurological Sciences, 2011, 32, 619-623.	1.9	5
416	Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. Journal of Headache and Pain, 2014, 15, 88.	6.0	5
417	Is drug treatment of psychogenic nonepileptic seizures effective?. Epilepsy and Behavior, 2019, 98, 288-289.	1.7	5
418	Self-reporting versus clinical scrutiny: the value of adding questionnaires to the routine evaluation of seizure disorders. An exploratory study on the differential diagnosis between epilepsy and psychogenic nonepileptic seizures. Epilepsy and Behavior, 2019, 90, 191-196.	1.7	5
419	Risk of seizure recurrence in people with single seizures and early epilepsy – Model development and external validation. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 26-32.	2.0	5
420	Early prognosis of epilepsy. Effects of treatment in the first follow-up year. Italian Journal of Neurological Sciences, 1986, 7, 421-429.	0.1	4
421	Diagnosis of diabetic polyneuropathy Correlation between clinical and instrumental findings and assessment of simple diagnostic criteria. Italian Journal of Neurological Sciences, 1988, 9, 577-582.	0.1	4
422	Exposure to Exogenous Gangliosides and Guillain-Barré Syndrome. Neuroepidemiology, 1995, 14, 45-48.	2.3	4
423	A case-control study on alcohol and seizures: study design, protocol, and data collection. Italian Journal of Neurological Sciences, 1997, 18, 119-124.	0.1	4
424	Response to Dr. Jaretzki's letter on video-assisted thoracoscopic extended thymectomy. Journal of the Neurological Sciences, 2004, 217, 235-236.	0.6	4
425	The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications?. Expert Review of Neurotherapeutics, 2011, 11, 1759-1767.	2.8	4
426	Invitation to participate in the EpiNet-Firsttrials. Epilepsia, 2015, 56, 807-807.	5.1	4
427	Relevance of clinical context in the diagnosticâ€therapeutic approach to status epilepticus. Epilepsia, 2016, 57, 1527-1529.	5.1	4
428	Is firstly diagnosed ALS really ALS? Results of a population-based study with long-term follow-up. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 221-226.	1.7	4
429	Sleep convulsive seizures predict lack of remission in genetic generalized epilepsies: A retrospective study from a single epilepsy center in Egypt. Acta Neurologica Scandinavica, 2017, 136, 528-535.	2.1	4
430	EpiNet as a way of involving more physicians and patients in epilepsy research: Validation study and accreditation process. Epilepsia Open, 2017, 2, 20-31.	2.4	4
431	Midazolam vs diazepam in prolonged seizures in children: A pharmacoeconomic approach. Acta Neurologica Scandinavica, 2018, 137, 24-28.	2.1	4
432	No Evidence of a Causal Role of Antiepileptic Drug Treatment with Regard to the Development of Dementia. Journal of the American Geriatrics Society, 2018, 66, 1850-1852.	2.6	4

#	Article	IF	CITATIONS
433	Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. Epilepsy and Behavior, 2019, 92, 14-17.	1.7	4
434	Impact of environmental factors and physical activity on disability and quality of life in CIDP. Journal of Neurology, 2020, 267, 2683-2691.	3.6	4
435	Myoelectrically Controlled FES to Enhance Tenodesis Grip in People With Cervical Spinal Cord Lesion: A Usability Study. Frontiers in Neuroscience, 2020, 14, 412.	2.8	4
436	Self-Report questionnaires for the diagnosis of psychogenic non-epileptic seizures in clinical practice. A comprehensive review of the available instruments. Seizure: the Journal of the British Epilepsy Association, 2020, 79, 30-43.	2.0	4
437	Trends in survival of ALS from a population-based registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 344-352.	1.7	4
438	Knowledge and attitudes of neurologists toward epilepsy surgery: an Italian survey. Neurological Sciences, 2022, 43, 4453-4461.	1.9	4
439	The epidemiology of inflammatory polyradiculoneuropathy. A critical review of the distribution, characteristics and outcome of the disease. Italian Journal of Neurological Sciences, 1991, 12, 63-73.	0.1	3
440	The Cochrane Collaboration in Neurology: Acquisitions, Research, and New Initiatives. Neuroepidemiology, 2001, 20, 153-159.	2.3	3
441	Teaching of neuroepidemiology in Europe: time for action. European Journal of Neurology, 2004, 11, 795-799.	3.3	3
442	Primary prevention of epilepsy in patients with different epileptogenic conditions. Expert Review of Neurotherapeutics, 2004, 4, 945-952.	2.8	3
443	HLA-DRB1 polymorphisms distribution in chronic dysimmune polyneuropathy. Neuromuscular Disorders, 2008, 18, 967-969.	0.6	3
444	Inter-rater agreement in the assessment of response to motor and cognitive rehabilitation of children and adolescents with epilepsy. European Journal of Paediatric Neurology, 2011, 15, 254-259.	1.6	3
445	When and how to stop antiepileptic drugs. Epileptology, 2013, 1, 17-20.	0.4	3
446	Use of the EpiNet database for observational study of status epilepticus in Auckland, New Zealand. Epilepsy and Behavior, 2015, 49, 164-169.	1.7	3
447	Do neurologists around the world agree when diagnosing epilepsy? – Results of an international EpiNet study. Epilepsy Research, 2018, 139, 43-50.	1.6	3
448	A validation study of the clinical diagnosis of Dup15q syndrome: Which symptoms matter most?. Seizure: the Journal of the British Epilepsy Association, 2020, 74, 26-30.	2.0	3
449	The management of epilepsy in clinical practice: Do the timing and severity of the disease influence the priorities of patients and the caring physicians? Data from the EPINEEDS study. Epilepsy and Behavior, 2021, 114, 107201.	1.7	3
450	Antiseizure medication in patients with Glioblastoma- a collaborative cohort study. Seizure: the Journal of the British Epilepsy Association, 2021, 87, 107-113.	2.0	3

#	Article	IF	CITATIONS
451	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane Library, 2021, 2021, CD007144.	2.8	3
452	Geographical clusters of amyotrophic lateral sclerosis and the Bradford Hill criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 329-343.	1.7	3
453	Reye's syndrome. Neurology, 1985, 35, 1338-1338.	1.1	3
454	Incidence of Acute Transverse Myelitis in Rochester, Minnesota, 1970–1980, and Implications with Respect to Influenza Vaccine. Neuroepidemiology, 1982, 1, 176-188.	2.3	2
455	Pharmacological Treatment of Primary Headache: Analysis of Current Practice From a Drug Utilization Study. Headache, 1987, 27, 345-350.	3.9	2
456	A Randomized Clinical Trial of the Efficacy and Safety of the Treatment of the First Unprovoked Epileptic Seizure. Neuroepidemiology, 1992, 11, 50-51.	2.3	2
457	Audit of care of acute inflammatory polyradiculoneuropathy in Italy. Pharmacoepidemiology and Drug Safety, 1995, 4, 137-146.	1.9	2
458	Epilepsy, risks and insurance. Seizure: the Journal of the British Epilepsy Association, 1995, 4, 85-86.	2.0	2
459	The management of a first seizure-Still a major debate. Epilepsia, 2008, 49, 1-1.	5.1	2
460	The EpiNet projectâ€"Invitation to participate in investigatorâ€led clinical research. Epilepsia, 2010, 51, 1919-1920.	5.1	2
461	Circulating cytokines and growth factors in professional soccer players: correlation with <i>in vitro</i> i>â€induced motor neuron death. European Journal of Neurology, 2011, 18, 85-92.	3.3	2
462	The value of epidemiology in headache. Journal of Headache and Pain, 2015, 16, A43.	6.0	2
463	The Basic Structure of a Randomized Clinical Trial. Frontiers of Neurology and Neuroscience, 2016, 39, 1-7.	2.8	2
464	General Overview, Conclusions, and Future Directions. Frontiers of Neurology and Neuroscience, 2016, 39, 154-162.	2.8	2
465	Epidemiology and familial clustering of pediatric epilepsy in the geographic isolate of Ischia. Epilepsy Research, 2019, 154, 86-89.	1.6	2
466	Risk factors for neonatal seizures: A case–control study in the province of Parma, Italy. Epilepsy and Behavior, 2020, 107, 107075.	1.7	2
467	Epilepsy in Psychiatric Disorders. Neuropsychiatric Symptoms of Neurological Disease, 2016, , 289-302.	0.3	2
468	Neurovascular and infectious disease phenotype of acute stroke patients with and without COVID-19. Neurological Sciences, 2022, 43, 4619-4625.	1.9	2

#	Article	IF	CITATIONS
469	Usefulness and significance of the concept of leukoaraiosis in the study of dementia. Italian Journal of Neurological Sciences, 1990, 11, 429-435.	0.1	1
470	Costs of epilepsy care in referral centers in Italy. European Journal of Health Economics, 2000, 1, 111-115.	0.2	1
471	Fact-finding study about knowledge and interest in quality of life assessment among neurologists. Neurological Sciences, 2004, 25, $114-5$.	1.9	1
472	Methodology of studies on the epidemiology of headache. Neurological Sciences, 2004, 25, s70-s73.	1.9	1
473	MIDAS questionnaire in the emergency setting. Neurological Sciences, 2004, 25, s274-s275.	1.9	1
474	ALS and military service. Neurology, 2005, 65, 972-972.	1.1	1
475	Epilepsy. Current Opinion in Neurology, 2007, 20, 169-174.	3.6	1
476	G.P.15.15 The SOLE questionnaire: Development and validation of a new instrument for measuring quality of life in children with neuromuscular disorders. Neuromuscular Disorders, 2007, 17, 868.	0.6	1
477	Stroke in neurological services in Italy. Neurology International, 2009, 1, 8.	2.8	1
478	Comment on "Factors influencing clinical features of absence seizures― Epilepsia, 2009, 50, 2003-2004.	5.1	1
479	Specific language disorders and season of birth: Underlying environmental factors or chance findings?. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 836-840.	1.3	1
480	Use of epinet database for observational study of status epilepticus in Auckland, New Zealand. Journal of the Neurological Sciences, 2015, 357, e143-e144.	0.6	1
481	Do neurologists around the world agree when diagnosing epilepsy? - Results of a multinational epinet study. Journal of the Neurological Sciences, 2015, 357, e28.	0.6	1
482	The epinet-first trials now recruiting patients with newly diagnosed epilepsy. Journal of the Neurological Sciences, 2015, 357, e144.	0.6	1
483	Peculiarities of Neurological Disorders and Study Designs. Frontiers of Neurology and Neuroscience, 2016, 39, 8-23.	2.8	1
484	Use of cell phones and brain tumors: a true association?. Neurological Sciences, 2017, 38, 713-714.	1.9	1
485	EpiNet study of incidence of status epilepticus in Auckland, New Zealand: Methods and preliminary results. Epilepsia, 2018, 59, 144-149.	5.1	1
486	Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues― Archives of Physical Medicine and Rehabilitation, 2018, 99, 1688-1689.	0.9	1

#	Article	IF	CITATIONS
487	Generation and validation of algorithms to identify subjects with dementia using administrative data. Neurological Sciences, 2019, 40, 2155-2161.	1.9	1
488	Invitation to participate in a prospective case–control study of sudden unexpected death in epilepsy. Epilepsia, 2021, 62, 1280-1281.	5.1	1
489	Does diagnostic delay impact on the outcome of epilepsy?. Epilepsia Open, 2021, 6, 470-471.	2.4	1
490	ALS incidence and population aging in Northern Italy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 236-241.	1.7	1
491	Methodological Demands on Observational Studies of Outcomes After Epilepsy Surgery. , 2015, , 5-18.		1
492	The Use of Antiepileptic Drugs in Newly Diagnosed Epilepsy. , 2010, , 1499-1503.		1
493	Treatment of Drug Resistant Epilepsy. , 2010, , 1559-1562.		1
494	Guillain-Barr \tilde{A} \otimes Syndrome Following (A/New Jersey/76) Influenza (Swine Flu) Vaccine: Epidemic or Artifact?. , 1986, , 249-254.		1
495	ILAE epidemiology commission report: introduction to the supplement. Epilepsia, 2011, 52 Suppl 7, 1.	5.1	1
496	Drug treatments and interactions, disease progression and quality of life in ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 415-423.	1.7	1
497	Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurological Sciences, 0, , .	1.9	1
498	Use of plasma levels for antiepileptic drug monitoring in clinical practice. Italian Journal of Neurological Sciences, 1992, 13, 59-65.	0.1	0
499	Should Anti-Epileptic Drugs be Used for Preventing Seizures after Acute Traumatic Brain Injury?. Neuroepidemiology, 2003, 22, 100-100.	2.3	0
500	G.P.15.16 Importance of self-report in pediatric quality of life assessment: Experience with the SOLE questionnaire in children with neuromuscular disorders. Neuromuscular Disorders, 2007, 17, 868-869.	0.6	0
501	<i>To the Editors:</i> Epilepsia, 2007, 48, 1418-1419.	5.1	0
502	Introduction. Epilepsia, 2009, 50, 1-3.	5.1	0
503	Reply. Epilepsia, 2010, 51, 723-723.	5.1	0
504	External validation of a prognostic index. Trials, 2013, 14, .	1.6	0

#	Article	IF	Citations
505	Epilepsy management and clinical research could be improved in low and middle income countries (LMICs) by epinet database. Journal of the Neurological Sciences, 2015, 357, e24.	0.6	0
506	Epidemiological and clinical aspects of amyotrophic lateral sclerosis in Republic of Moldova. Journal of the Neurological Sciences, 2015, 357, e193-e194.	0.6	0
507	Coffee and Amyotrophic Lateral Sclerosis. , 2015, , 429-434.		0
508	In response: Towards a quantitative assessment of psychogenic nonepileptic seizures. Epilepsia, 2016, 57, 1011-1012.	5.1	0
509	Editorial: Novel Perspectives in the Treatment of Epilepsy. Current Pharmaceutical Design, 2018, 23, 5543-5545.	1.9	0
510	Author response to a Letter to the Editor entitled: Preventive effect of coffee and tea on amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 618-618.	1.7	0
511	Epilepsy and cancer. , 2019, , 177-186.		0
512	Editorial: Novel Perspectives in the Treatment of Epilepsy. Current Pharmaceutical Design, 2017, 23, .	1.9	0
513	Long-term risk of chronic epilepsy in adults after post-anoxic coma and refractory status epilepticus: a retrospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 793-794.	1.9	O
514	ChapitreÂ4. Troubles de l'humeur chezÂdesÂadultes etÂdesÂenfants souffrant d'épilepsieÂ: définiti et©pidémiologie. , 2015, , 42-51.	ons	0